CL2020000733A1 - Proteína de fusión que comprende una porción de fgf-18. - Google Patents

Proteína de fusión que comprende una porción de fgf-18.

Info

Publication number
CL2020000733A1
CL2020000733A1 CL2020000733A CL2020000733A CL2020000733A1 CL 2020000733 A1 CL2020000733 A1 CL 2020000733A1 CL 2020000733 A CL2020000733 A CL 2020000733A CL 2020000733 A CL2020000733 A CL 2020000733A CL 2020000733 A1 CL2020000733 A1 CL 2020000733A1
Authority
CL
Chile
Prior art keywords
fgf
fusion protein
cartilage
osteoarthritis
fused
Prior art date
Application number
CL2020000733A
Other languages
English (en)
Inventor
Anne Gigout
Christian Brenneis
Thomas Rysiok
Stefan Zielonka
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2020000733A1 publication Critical patent/CL2020000733A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVAS PROTEÍNAS DE FUSIÓN QUE COMPRENDEN UNA PORCIÓN DE FGF-18 FUSIONADA A UNA PORCIÓN ANTI-NGF. DICHA PROTEÍNA DE FUSIÓN PUEDE SER UTILIZADA PARA EL TRATAMIENTO DEL DESORDEN DE UN CARTÍLAGO TAL COMO OSTEOARTRITIS O DAÑO AL CARTÍLAGO.
CL2020000733A 2017-09-21 2020-03-20 Proteína de fusión que comprende una porción de fgf-18. CL2020000733A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17192467 2017-09-21
EP18182696 2018-07-10

Publications (1)

Publication Number Publication Date
CL2020000733A1 true CL2020000733A1 (es) 2020-10-02

Family

ID=63557503

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000733A CL2020000733A1 (es) 2017-09-21 2020-03-20 Proteína de fusión que comprende una porción de fgf-18.

Country Status (15)

Country Link
US (1) US11572395B2 (es)
EP (1) EP3684791A1 (es)
JP (1) JP7237945B2 (es)
KR (1) KR20200054300A (es)
CN (1) CN111132997A (es)
AU (1) AU2018337686B2 (es)
BR (1) BR112020005035A2 (es)
CA (1) CA3074483A1 (es)
CL (1) CL2020000733A1 (es)
IL (1) IL273271A (es)
MX (1) MX2020003211A (es)
PH (1) PH12020550099A1 (es)
RU (1) RU2020113713A (es)
SG (1) SG11202001772SA (es)
WO (1) WO2019057805A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019366956A1 (en) * 2018-10-23 2021-05-20 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
CN113151185B (zh) * 2020-11-17 2023-06-23 苏州仁端生物医药科技有限公司 分泌抗fgf18单克隆抗体杂交瘤细胞株及其单抗、应用
IL310700A (en) * 2021-08-09 2024-04-01 Merck Patent Gmbh Proteins that uncouple cell-mediated tumor cytotoxicity from proinflammatory cytokine release
CN117721115A (zh) * 2022-09-06 2024-03-19 深圳瑞吉生物科技有限公司 用于治疗骨关节炎的mRNA及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264175B1 (en) 1996-10-16 2012-11-21 ZymoGenetics, Inc. Fibroblast growth factor homologs
US7470665B2 (en) 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
JP4754823B2 (ja) 2002-10-07 2011-08-24 ザイモジェネティクス， インコーポレイテッド Ｆｇｆ１８の投与方法
US20050202043A1 (en) * 2004-02-23 2005-09-15 Borean Pharma A/S Multimerised HIV fusion inhibitors
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
EP2054050B1 (en) 2006-08-25 2012-08-08 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
RS63063B1 (sr) * 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antitela i njihova upotreba
WO2015114150A1 (en) 2014-02-02 2015-08-06 Medimmune Limited Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain
US10982008B2 (en) 2014-12-05 2021-04-20 Merck Patent Gmbh Domain-exchanged antibody
WO2017025611A1 (en) 2015-08-13 2017-02-16 Merck Patent Gmbh Combination composition comprising fgf-18 compound

Also Published As

Publication number Publication date
US11572395B2 (en) 2023-02-07
IL273271A (en) 2020-04-30
RU2020113713A3 (es) 2022-03-03
MX2020003211A (es) 2020-09-21
BR112020005035A2 (pt) 2020-09-15
US20200299347A1 (en) 2020-09-24
KR20200054300A (ko) 2020-05-19
AU2018337686B2 (en) 2023-04-20
SG11202001772SA (en) 2020-04-29
RU2020113713A (ru) 2021-10-21
JP7237945B2 (ja) 2023-03-13
WO2019057805A1 (en) 2019-03-28
AU2018337686A1 (en) 2020-03-19
JP2020536511A (ja) 2020-12-17
PH12020550099A1 (en) 2020-09-14
CN111132997A (zh) 2020-05-08
CA3074483A1 (en) 2019-03-28
EP3684791A1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CL2020000733A1 (es) Proteína de fusión que comprende una porción de fgf-18.
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
CL2017001584A1 (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2017001369A1 (es) Proceso para manipular el nivel del contenido de glicano de una glicoproteina
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
EA201790173A1 (ru) Антитела, связывающие axl
BR112017006112A2 (pt) formulação de proteína de fusão recombinante
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
HK1250731A1 (zh) 用於治療癌症的免疫原性融合蛋白
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PH12017500742A1 (en) Statherin peptides
EA202091567A1 (ru) Химерные белки мти
SG11202000775SA (en) Fusion tags for recombinant protein expression
DK3561056T3 (da) Peptid til behandling af aldersrelateret makuladegeneration
CL2017001633A1 (es) Método de manufactura de proteína.
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite